|
|
News Breaks
|
November 18, 2009
|
| 07:06 EDT |  | IMGN |
| theflyonthewall.com: | ImmunoGen option prices elevated into data | | ImmunoGen closed at $8.58. ImmunoGen most advanced compound, trastuzumab-DM1 (breast cancer treatment) is in Phase three testing, and data is expected before year end. ImmunGen December 7.5 straddle is priced at $3.00, January 7.5 straddle is priced at $3.90. IMGN December and January option implied volatility of 145 is above its 26-week average of 78 according to Track Data, suggesting large price movement. :theflyonthewall.com |
|
|
News For IMGN From The Last 14 Days Check below for free stories on IMGN the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 27, 2012
|
| 06:43 EDT |  | IMGN |
| | 06:42 EDT |  | IMGN |
|
|
|
|
|
Subscribe for More Information